Drugs / Fourth Genenation of CAR-T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03778346 | Nov 2018 → Jun 2022 | — | The Sixth Affiliated Hospital of Wenzhou Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fourth Genenation of CAR-T Cells | “Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells to treat Relapsed/Refractory multiple myeloma” NCT03778346 ↗ |
| Action | Deplete | “The basic principle is to use the patient's own immune cells to clear cancer cells.” NCT03778346 ↗ |
| Modality | Cell therapy | “fourth-generation CAR-T cells” PMID 33767695 ↗ Mar 2021 |